Robert Caivano
Family · Fort Worth, TXNPI 1891107561
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,092 of the $8,304 with a category attached, or 85.4%. It is spread thinly across 38 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,964 and has fallen 56.3% since, to $1,296 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Novo Nordisk$999
- AbbVie$856
- Lilly USA, LLC$837
- AstraZeneca$581
- GSK$422
- plus $3K from 32 others
What the payments were for
- Consulting fees$1,20014%
- Food & beverage$7,09285%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 10 | $1,335 |
| Novo Nordisk | 61 | $999 |
| AbbVie(2 entities) | 50 | $856 |
| Lilly USA, LLC | 55 | $837 |
| AstraZeneca | 29 | $581 |
| GSK | 23 | $422 |
| Boehringer Ingelheim | 20 | $315 |
| Pfizer | 28 | $298 |
| Dexcom, Inc. | 15 | $296 |
| Bayer | 18 | $291 |
| Astellas Pharma US Inc | 19 | $283 |
| Johnson & Johnson | 14 | $217 |
| Amgen | 13 | $216 |
| Eisai Inc. | 9 | $172 |
| Amarin Pharma, Inc. | 11 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $150 |
| Novartis | 6 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $85 |
| Exact Sciences | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 4 | $64 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Abbott | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Upsher-smith Laboratories LLC | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Merck | 2 | $30 |
| Nevro Corp. | 2 | $30 |
| Antares Pharma, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Althera Pharmaceuticals LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$8,304 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 131 | $126,003 |
| OzempicSemaglutide | 54 | $92,361 |
| TrulicityDulaglutide | 33 | $63,067 |
| EliquisApixaban | 57 | $54,539 |
| MounjaroTirzepatide | 24 | $36,535 |
| JanuviaSitagliptin Phosphate | 21 | $35,272 |
| XareltoRivaroxaban | 27 | $26,161 |
| QuliptaAtogepant | 14 | $25,243 |
| FarxigaDapagliflozin Propanediol | 19 | $22,182 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $18,576 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $14,533 |
| VascepaIcosapent Ethyl | 11 | $9,461 |
| LinzessLinaclotide | 15 | $9,101 |
| Repatha SyringeEvolocumab | 14 | $7,982 |
| Tamsulosin Hcl | 164 | $3,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $315 | $126,003131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $837 | $99,60357 claims |
| Novo NordiskOzempic | $999 | $92,36154 claims |
| PfizerEliquis, Paxlovid | $298 | $57,39878 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $581 | $40,75835 claims |
| MerckJanuvia | $30 | $35,27221 claims |
| AbbVieQulipta, Linzess | $856 | $34,34429 claims |
| Johnson & JohnsonXarelto | $217 | $26,16127 claims |
| GSKTrelegy Ellipta | $422 | $14,53314 claims |
| Sanofi-aventis U.S. LLCLantus | $36 | $1,35911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.